Register for free to listen to this article
Listen with Speechify
0:00
1:00

ROCKVILLE, Md. – OriGene Technologies Inc. announced theacquisition of Marligen Biosciences Inc., a provider of cutting-edge multiplexassays for the Luminex xMAP platform for protein and gene expression profiling assays and testingservices, and DNA and RNA purification kits. 

 

The acquisition reinforces OriGene's leading position in thebio-medical research industry by expanding the scope of its gene centric toolboxportfolio and further represents another step in OriGene's aggressive growthplan.

 

The acquisition will enhance OriGene's gene centric productportfolio to include new assay panels and custom assays for drugdiscovery.  Leveraging OriGene'shigh throughput monoclonal antibody production capability, OriGene intends tocomplete its development of high quality assay panels and custom assays forresearchers that will dramatically hasten and increase efficiencies for drugdiscovery. OriGene's mammalian cell expressed proteins maintain the mostauthentic protein structure, post-translational modifications and functions. 

 

WithMarligen's assay development expertise and a strong menu of kits and reagents,and the complementary assets and strengths of OriGene's product line, OriGenewill provide a complete product solution to fully address the needs of drugdiscovery researchers. By acquiring Marligen, OriGene has increased itscritical mass and enhanced its competitive strength for creating a gene centricproduct line which researchers can use to accelerate drug discovery andcellular analysis.  All ofMarligen's key talent will be retained by OriGene at its new state-of-art researchfacility in Rockville, Md. 

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue